JP2024506602A - 浮腫および関連状態の処置のための選択的ｒｏｃｋ２阻害 - Google Patents

浮腫および関連状態の処置のための選択的ｒｏｃｋ２阻害 Download PDF

Info

Publication number
JP2024506602A
JP2024506602A JP2023547568A JP2023547568A JP2024506602A JP 2024506602 A JP2024506602 A JP 2024506602A JP 2023547568 A JP2023547568 A JP 2023547568A JP 2023547568 A JP2023547568 A JP 2023547568A JP 2024506602 A JP2024506602 A JP 2024506602A
Authority
JP
Japan
Prior art keywords
compound
selective
selective rock2
rock2 inhibitor
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023547568A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024506602A5 (https=
Inventor
リー，イーサック
エス． チェン，クリストファー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Harvard University
Original Assignee
Boston University
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University, Harvard University filed Critical Boston University
Publication of JP2024506602A publication Critical patent/JP2024506602A/ja
Publication of JP2024506602A5 publication Critical patent/JP2024506602A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023547568A 2021-02-04 2022-02-03 浮腫および関連状態の処置のための選択的ｒｏｃｋ２阻害 Pending JP2024506602A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163145526P 2021-02-04 2021-02-04
US63/145,526 2021-02-04
US202163209324P 2021-06-10 2021-06-10
US63/209,324 2021-06-10
US202163228404P 2021-08-02 2021-08-02
US63/228,404 2021-08-02
PCT/US2022/015072 WO2022169946A1 (en) 2021-02-04 2022-02-03 Selective rock2 inhibition for treatment of edema and associated conditions

Publications (2)

Publication Number Publication Date
JP2024506602A true JP2024506602A (ja) 2024-02-14
JP2024506602A5 JP2024506602A5 (https=) 2025-02-12

Family

ID=82742517

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023547568A Pending JP2024506602A (ja) 2021-02-04 2022-02-03 浮腫および関連状態の処置のための選択的ｒｏｃｋ２阻害

Country Status (4)

Country Link
US (1) US20240131029A1 (https=)
EP (1) EP4288075A4 (https=)
JP (1) JP2024506602A (https=)
WO (1) WO2022169946A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201801226D0 (en) 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase
EP4393917A4 (en) * 2021-09-18 2025-09-10 Beijing Tide Pharmaceutical Co Ltd SOLID FORM OF A RHO-ASSOCIATED PROTEIN KINASE INHIBITOR OR SOLVATE THEREOF, METHOD OF PREPARATION AND USE THEREOF
CN117843618A (zh) * 2022-08-29 2024-04-09 北京沐华生物科技有限责任公司 一种ep300/cbp调节剂及其制备方法和用途
WO2026047205A2 (en) * 2024-08-30 2026-03-05 Université de Liège Treatments for lymphedema

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20121126A1 (es) 2006-12-21 2012-08-24 Plexxikon Inc Compuestos pirrolo [2,3-b] piridinas como moduladores de quinasa
WO2015054654A1 (en) 2013-10-10 2015-04-16 Fibralign Corporation Method and device for lymphedema treatment
EP3262041A4 (en) * 2015-02-27 2018-08-01 Lycera Corporation Indazolyl thiadiazolamines and related compounds for inhibition of rho-associated protein kinase and the treatment of disease
WO2017044454A1 (en) 2015-09-11 2017-03-16 Propagenix Inc. Ex vivo proliferation of epithelial cells
EP3504204A4 (en) * 2016-08-26 2020-05-27 Lycera Corporation INDAZOLYL-L, 2,4-THIADIAZOLAMINE AND RELATED COMPOUNDS FOR INHIBITING RHO-ASSOCIATED PROTEIN KINASES AND FOR TREATING DISEASES
GB201801226D0 (en) * 2018-01-25 2018-03-14 Redx Pharma Plc Modulators of Rho-associated protein kinase

Also Published As

Publication number Publication date
EP4288075A1 (en) 2023-12-13
US20240131029A1 (en) 2024-04-25
WO2022169946A1 (en) 2022-08-11
EP4288075A4 (en) 2024-12-11

Similar Documents

Publication Publication Date Title
JP2024506602A (ja) 浮腫および関連状態の処置のための選択的ｒｏｃｋ２阻害
JP7432562B2 (ja) アリール受容体モジュレーターならびにその作製および使用方法
Liang et al. Thalidomide inhibits fibronectin production in TGF-β1-treated normal and keloid fibroblasts via inhibition of the p38/Smad3 pathway
Liu et al. Role of NLRC5 in progression and reversal of hepatic fibrosis
JP6931002B2 (ja) ベンゾチアゾール両親媒性物質
KR20190127576A (ko) 암 세포의 이동과 침윤 억제를 통한 암 전이 억제제
EA201892460A1 (ru) Производные аденина как ингибиторы протеинкиназ
CN109415342A (zh) 用于治疗纤维化的wnt抑制剂
US20040014814A1 (en) Compositions and methods for delaying preventing rejuvenating or reversing senescence in cells
JP6778200B2 (ja) Ｓｐｉｒａｎｔｈｅｓ ｓｉｎｅｎｓｉｓ抽出物を含有する組成物およびその薬学的適用
KR20190038840A (ko) 피부 및/또는 모발 복구를 위한 5-하이드록시트립타민 1b 수용체-자극제
KR20180101322A (ko) 뇌졸중으로부터의 회복을 위한 방법 및 조성물
JP2005504719A (ja) 細胞、組織、器官、髪及び爪を若返らせる方法及び組成物
JP6593619B2 (ja) 血管攣縮抑制剤
KR20160097165A (ko) 베이지 및 갈색 지방세포 분화 유도용 조성물 및 이의 방법
JP6788592B2 (ja) 血管新生阻害用ｃ−１９ステロイド
US20230126139A1 (en) HETEROCYCLIC INHIBITORS OF RHO GTPases FOR THE TREATMENT OF DISEASE
CN114560817B (zh) 一种用于抑制纤维化的小分子药物及其应用
EP4545527A1 (en) Ester compounds and use thereof
KR102322102B1 (ko) 염증성 질환의 예방, 개선 또는 치료용 조성물
JP7580123B2 (ja) 血管新生関連疾患の予防又は治療用医薬組成物
KR102623917B1 (ko) 암 세포의 이동과 침윤 억제를 통한 암 전이 억제제
Schelbergen et al. The S100A9 inhibitor paquinimod (ABR-215757) reduces synovial activation, osteophyte formation and cartilage damage in experimental osteoarthritis
WO2022255250A1 (ja) 筋再生促進剤
EP3960748A1 (en) Composition for the treatment of the side effects of radiotherapy and/or chemotherapy

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250203

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250203

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260424